Research On Accounting Information Disclosure Of Er Kang Pharmaceutical

Accounting information reflects the situation of the company's operation on many levels,it is an effective way to communicate with the investors.The quality of accounting information disclosure of listed companies will not only affect the decision-making of various information users,but also affect the effective operation and healthy development of the securities market.Despite the fact that China's capital market is becoming increasingly standardized,relevant departments will constantly update and improve accounting standards according to the current situation and existing problems exposed in accounting information disclosure.For instance,the new accounting standards in 2019 stipulate the changed contents and reasons of accounting policy disclosed in the notes to financial statements.However,the illegal disclosure of accounting information of listed companies has always existed.The illegal disclosure of accounting information will not only breathes upon company's operation and reputation,but also reduces the enthusiasm of investors and the effectiveness of capital market resource allocation.It is becoming prominently paramount for a company to disclose accounting information truly and comprehensively.Standardized accounting information disclosure has a positive effect on the healthy and effective development of enterprises,also,the protection of illegal rights and interests of small and medium-sized shareholders and investors.At the same time.On the basis of the research results on accounting information disclosure at home and abroad,with the combination of relevant theories system requirements,this paper adopts documentation,case study and deductive analysis methods to analyze the current situation,existing problems and causes of accounting information disclosure of Er-kang Pharmaceutical.This paper discovers its internal control problem,which delays the transfer of accounting information such as sales returns;also,the irregularity of accounting treatment and the lack of supervision of the internal audit department have affected the disclosure of accounting information;the inadequate market supervision and the imperfect and lack of details formulation of relevant standards and systems,all lead to the lack of clear standards in the actual implementation;meanwhile,the professional qualities and ethics of some relevant personnel involved in the accounting information disclosure of Er-kang Pharmaceutical fail to meet the corresponding standards,resulting in the accounting personnel failing to deal with them correctly according to the relevant standards,systems and the actual situation.In addition,the internal auditors and external auditors failed finding out the problems existing in the financial reports meanwhile,issued the standard unqualified audit reports.Furthermore,defects in the supervision of related parties transactions make it difficult to collect evidence for cross-border transactions.In view of the above reasons,some suggestions are put forward to improve the disclosure accounting information of Er-kang Pharmaceutical,such as enhancing the market oversight,improving the supervision measures of related parties transactions.At the same time,this paper intends to provide some guidance and reference for other listed companies in pharmaceutical industry to improve accounting information disclosure for the purpose of continuously optimizing the effectiveness of decision-making on accounting information.